Modality
siRNA
MOA
TNFi
Target
C5
Pathway
PD-1/PD-L1
EpilepsyEoE
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Aug 2026
Phase 1Current
NCT05332792
2,582 pts·EoE
2017-01→2025-07·Completed
NCT04572155
548 pts·EoE
2021-03→2026-08·Not yet recruiting
3,130 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-099mo agoPh2 Data· EoE
2026-08-155mo awayPh2 Data· EoE
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Complet…
P1/2
Not yet…
Catalysts
Ph2 Data
2025-07-09 · 9mo ago
EoE
Ph2 Data
2026-08-15 · 5mo away
EoE
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05332792 | Phase 1/2 | EoE | Completed | 2582 | eGFR |
| NCT04572155 | Phase 1/2 | EoE | Not yet recr... | 548 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Elratapinarof | Halozyme | Phase 2 | C5 |